12:00 AM
 | 
Oct 20, 2016
 |  BC Extra  |  Clinical News

Gilead's selonsertib heading for Phase III NASH trial

Gilead Sciences Inc. (NASDAQ:GILD) said anti-fibrotic activity shown in a Phase II study of selonsertib ( GS-4997) to treat non-alcoholic steatohepatitis warrants advancement of the compound into Phase III testing in the indication.

Among 67 evaluable patients in the open-label Phase II trial, high and low doses...

Read the full 227 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >